查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018689

肌萎缩侧索硬化症 (ALS) 治疗市场：治疗方法、类型、治疗阶段、给药途径和分销管道划分－2026-2032 年全球市场预测

Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肌萎缩侧索硬化症 (ALS) 治疗市场价值将达到 7.3306 亿美元，到 2026 年将增长至 7.8576 亿美元，到 2032 年将达到 11.8864 亿美元，年复合增长率为 7.14%。

主要市场统计数据
基准年 2025 7.3306亿美元
预计年份：2026年 7.8576亿美元
预测年份 2032 1,188,640,000 美元
复合年增长率 (%) 7.14%

对 ALS 的临床和商业性现状进行简要概述，以促进战略优先排序和循证项目决策。

肌萎缩侧索硬化症 (ALS) 是临床医生、研究人员和相关人员面临的最复杂的神经退化性疾病之一。此疾病的临床异质性，涵盖遗传性和散发性病因，对传统的研发模式提出了挑战，凸显了临床试验设计、生物标记选择和治疗标靶选择精准性的重要性。因此，决策者必须整合分子标靶、症状治疗和支持疗法等方面的见解，以製定连贯的产品和产品组合策略。

治疗方法的创新、证据的进步以及医疗保健服务的变革，是如何重新定义 ALS 治疗的发展和商业化的？

肌萎缩侧索硬化症（ALS）的治疗前景正经历着变革性的转变，这主要得益于科学进步、监管政策的细微调整以及不断发展的治疗路径的融合。基因标靶治疗和反义寡核苷酸疗法正从实验性工具发展成为具有明确临床应用前景的候选疗法，促使生物製药公司重新评估其平台投资和合作策略。同时，干细胞疗法的研究也正从临床前模型推进到早期人体试验阶段，安全性、给药途径和病患选择正成为决定临床成功与否的关键因素。

评估美国关税政策变更对 2025 年神经系统药物价值链供应链、生产和取得的影响。

贸易和关税政策的变化对复杂的药品供应链的影响远不止成本上涨那么简单。美国2025年前后的关税格局变化，对生产策略、采购和定价的韧性提出了严峻的挑战。许多用于神经系统药物的活性成分和特殊辅料都来自全球各地，进口关税的提高可能会加剧投入成本的波动。为了应对这项挑战，各机构正在重新审视供应商多元化、近岸外包以及多源采购合约等方案，以维持供应的连续性并降低贸易政策变化带来的风险。

以细分为重点的综合分析，将治疗方法、患者亚群、给药途径和分销管道与其临床和商业性意义联繫起来。

了解市场需求和临床应用需要采用细分观点，将治疗方法与患者亚群、疾病阶段、给药途径和通路相匹配。基于治疗方法，市场可分为药物和治疗方法两大类。药物治疗方法包括Dextromethorphan/奎尼丁、Edaravone、Riluzole和托福生，而治疗方法则包括基因疗法和干细胞疗法。每种疗法都有其独特的临床特征、证据要求和给药途径。这种基于治疗方法的细分凸显了小分子对症药物和神经保护化合物倾向于沿用现有的海外通路，而基因疗法和细胞疗法则需要专门的给药环境和长期安全性监测。

对区域趋势的比较分析概述了主要地区的法规、临床研究和准入框架如何影响 ALS 治疗的开发和商业化。

区域趋势对肌萎缩侧索硬化症（ALS）治疗的调节路径、临床试验可行性和准入框架有显着影响。在美洲，监管机构和支付系统对申请设计和报销谈判有着强大的影响力，而成熟的研究网络则支持在检验新机制的临床试验中快速招募患者。此外，美洲集中了许多优秀的医疗中心，能够提供专业的鞘内和静脉注射注射疗法，而综合医疗保健系统在协调多学科诊疗方面发挥着至关重要的作用。

竞争与合作的动态揭示了投资组合策略、製造伙伴关係以及对病人参与的投资如何影响 ALS 治疗的成功。

肌萎缩侧索硬化症（ALS）治疗领域的竞争格局呈现出多元化的特点，既有成熟的神经系统疾病治疗产品组合，也有专注于生物技术创新的创新企业，还有致力于开发先进治疗方法的合约研究机构。大型製药企业和生技公司正积极推动以疾病分子机制为标靶的平台型疗法，而小规模的专业公司则专注于特定适应症、基于生物标记的队列研究或新型给药方案。这种多样性为策略联盟、授权协议和共同开发契约创造了机会，从而将科学专长与商业性规模相结合。

采取实际有效的策略措施，协调研发、供应链和进入工作，降低专案风险，加速病患获得治疗。

产业领导者必须将策略投资与实际情况结合，才能在管控风险的同时掌握治疗与商业性机会。优先考虑临床开发团队与以支付方为导向的证据团队之间的合作至关重要，这能确保在专案设计早期就整合试验终点、自然病程对照和健康经济学模型。这种协调一致有助于减少后续的准入障碍，并在产品上市时支持强有力的价值沟通。

混合方法研究框架结合了对专家的初步访谈和二手证据的整合，并采用严格的三角检验，检验了治疗和操作方面的见解。

本分析的研究途径结合了对同侪审查文献、监管指南和公共临床试验註册库的系统性回顾，以及针对临床、监管、供应链和商业领域的专家访谈。对神经科、临床试验首席研究员、卫生经济学家和供应链高管的访谈，为新兴治疗方法趋势、管理挑战和支付方期望提供了定性检验。辅助研究则整合了科学出版物、监管简报文件和已发布的治疗指南，以阐明治疗机制和临床终点。

从科学、营运和支付方考虑因素的交汇点出发，对将 ALS 治疗的进展转化为短期内患者可及性起着至关重要的作用，提供了全面的观点。

肌萎缩侧索硬化症（ALS）的治疗格局正处于转折点，分子层面的精准治疗、新型给药方式以及不断演变的证据预期相互交汇，重塑着药物研发和市场准入策略。基因标靶治疗治疗和细胞疗法的进步有望真正改变特定患者群体的疾病进程，而症状治疗和监测技术的改进则提升了疾病各个阶段患者的生活品质。然而，要实现这些机会，需要严格整合临床证据、生产能力以及面向支付方的价值论证。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肌萎缩侧索硬化症（ALS）治疗市场（依治疗方法划分）

  • 药物治疗
    • Dextromethorphan/奎尼丁
    • Edaravone
    • Riluzole
    • 託费尔森
  • 治疗方法
    • 基因治疗
    • 干细胞疗法

第九章 肌萎缩侧索硬化症（ALS）治疗市场：按类型划分

  • 遗传性肌萎缩性侧索硬化症
  • 散发性肌萎缩性侧索硬化症

第十章：肌萎缩侧索硬化症（ALS）治疗市场（依治疗阶段划分）

  • 晚期治疗
  • 早期治疗
  • 中期治疗

第十一章 肌萎缩侧索硬化症（ALS）治疗市场：依给药途径划分

  • 鞘内腔
  • 静脉
  • 口服

第十二章 肌萎缩侧索硬化症 (ALS) 治疗市场：依分销管道划分

  • 医院药房
  • 零售药房

第十三章 肌萎缩侧索硬化症（ALS）治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肌萎缩侧索硬化症（ALS）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 肌萎缩侧索硬化症（ALS）治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肌萎缩侧索硬化症（ALS）治疗市场

第十七章：中国肌萎缩侧索硬化症（ALS）治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AB Science SA
  • Alector, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aquestive Therapeutics, Inc.
  • Ascend Pharmaceuticals LLC
  • AstraEureka Pharmaceuticals
  • Biogen Inc.
  • BrainStorm Cell Limited
  • Cipla Limited
  • CorestemChemon Inc.
  • Coya Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • Dewpoint Therapeutics, Inc.
  • DR. REDDY'S LABORATORIES LIMITED
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals, LLC
  • GlaxoSmithKline PLC
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurimmune AG
  • Novartis AG
  • ONO PHARMACEUTICAL CO., LTD.
  • Orion Corporation
  • Orphazyme A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Treeway BV
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-AD36CD897F1B

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 733.06 million in 2025 and is projected to grow to USD 785.76 million in 2026, with a CAGR of 7.14%, reaching USD 1,188.64 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 733.06 million
Estimated Year [2026] USD 785.76 million
Forecast Year [2032] USD 1,188.64 million
CAGR (%) 7.14%

Concise contextualization of the ALS clinical and commercial landscape to inform strategic prioritization and evidence-driven program decisions

Amyotrophic lateral sclerosis represents one of the most complex neurodegenerative diseases confronting clinicians, researchers, and commercial stakeholders. The clinical heterogeneity of the condition, spanning familial and sporadic etiologies, challenges conventional development paradigms and elevates the importance of precision in trial design, biomarker selection, and therapeutic targeting. As a result, decision-makers must synthesize insights across molecular therapies, symptomatic agents, and supportive care to frame coherent product and portfolio strategies.

Recent advances in antisense modalities, targeted antioxidants, and repurposed symptomatic combinations have shifted clinical conversations from purely supportive management toward disease-modifying intent. Alongside these clinical developments, shifting regulatory expectations and heightened scrutiny on evidence of functional benefit have prompted sponsors to calibrate endpoints and invest in longitudinal natural history datasets. Consequently, commercial leaders must balance near-term access and reimbursement pathways for symptomatic products with longer-term investment in high-cost, high-complexity modalities.

This executive summary distills the most consequential trends, segmentation insights, regional dynamics, and actionable recommendations for organizations operating across the ALS treatment continuum. The goal is to equip executives with a concise, evidence-driven narrative that supports prioritization, risk mitigation, and the design of commercially viable development programs in a rapidly evolving therapeutic landscape.

How converging therapeutic innovation, evidence evolution, and care delivery transformation are redefining development and commercialization for ALS treatments

The ALS treatment landscape is undergoing transformative shifts driven by converging scientific advances, regulatory nuance, and evolving care pathways. Gene-targeted approaches and antisense oligonucleotides have matured from experimental tools into clinical candidates with clear translational potential, prompting biopharma organizations to re-evaluate platform investments and collaboration strategies. At the same time, stem cell therapy research has progressed from preclinical models to early human studies that emphasize safety, route of administration, and patient selection as critical determinants of translational success.

Parallel to therapeutic innovation, real-world evidence generation and digital biomarkers are reshaping how clinical benefit is demonstrated. Remote monitoring technologies and objective functional metrics are increasingly incorporated into trial protocols to capture granular changes in disease trajectory, enabling more sensitive detection of therapeutic signals. Payers and health technology assessment bodies are responding by seeking evidence that links surrogate improvements to meaningful patient-centric outcomes, thus influencing trial designs and post-approval evidence commitments.

Commercially, the distribution and administration complexities of advanced therapies are redefining channel strategies. Intrathecal and intravenous modalities necessitate specialized infusion centers and care coordination, which elevates the role of hospital pharmacies and integrated health systems in enabling patient access. Consequently, manufacturers are establishing center-of-excellence programs and partnering with clinical networks to streamline delivery, support adherence, and reduce logistical friction. Taken together, these shifts underscore an industry pivot toward integrated development and commercialization approaches that account for the entire patient journey from diagnosis to long-term follow-up.

Assessing the supply chain, manufacturing, and access implications of evolving United States tariff policies for neurological therapeutic value chains in 2025

Policy shifts in trade and tariffs have implications for complex therapeutic supply chains that extend beyond simple cost increments, and the unfolding tariff landscape in the United States for 2025 introduces material considerations for manufacturing strategy, procurement, and pricing resilience. Many active pharmaceutical ingredients and specialty excipients used in neurological therapeutics are sourced globally, and increased import duties can amplify input cost volatility. In response, organizations are reassessing supplier diversification, nearshoring options, and multi-sourcing agreements to preserve continuity of supply and mitigate exposure to trade policy shocks.

Beyond raw material costs, tariffs can influence the location of critical production steps such as fill-finish operations, cold chain logistics, and specialized biologics manufacturing. These operational shifts can extend lead times and increase the capital intensity of ensuring regulatory-compliant manufacturing footprints. Consequently, sponsors may accelerate investments in domestic manufacturing capabilities or long-term contractual commitments with contract manufacturing organizations that can absorb policy-driven margin pressure while guaranteeing capacity.

Importantly, the cumulative impact of tariffs also cascades into pricing and access strategies. Payers and procurement entities are likely to scrutinize price trajectories, particularly for high-cost, specialty therapies. Manufacturers may need to adopt more sophisticated value dossiers and risk-sharing arrangements to maintain formulary access under tightening budget constraints. In short, the tariffs scenario for 2025 reinforces the need for proactive supply chain risk management, flexible sourcing, and integrated commercial planning that anticipates regulatory, operational, and payer responses to increased cost pressures.

A segmentation-focused synthesis that links treatment modalities, patient subgroups, administration routes, and distribution channels to clinical and commercial implications

Understanding demand and clinical adoption requires a segmentation-aware perspective that aligns therapeutic modalities with patient subgroups, stages of disease, routes of administration, and distribution pathways. Based on treatment, the landscape divides into medication and therapies, where medication modalities include dextromethorphan/quinidine, edaravone, riluzole, and tofersen, while therapy approaches span gene therapy and stem cell therapy, each presenting distinct clinical profiles, evidence expectations, and delivery requirements. This treatment-based segmentation highlights that small-molecule symptomatic agents and neuroprotective compounds tend to follow established outpatient distribution channels, whereas gene-based and cellular therapies drive requirements for specialized administration settings and long-term safety surveillance.

Based on type, the dichotomy between familial ALS and sporadic ALS matters considerable for both development strategy and trial enrollment. Familial forms often support targeted molecular approaches with genetically defined mechanisms, enabling more precise patient selection and potentially more rapid proof-of-concept studies. Sporadic ALS, by contrast, demands broader population strategies and biomarker-driven stratification to address etiologic heterogeneity and demonstrate generalizability.

Based on treatment stage, early stage treatment, mid stage treatment, and advanced stage treatment each call for tailored endpoints, supportive care integrations, and risk-benefit considerations. Early stage interventions emphasize slowing progression and preserving function, necessitating sensitive outcome measures and proactive patient identification. Mid stage management focuses on symptom modulation and maintaining quality of life, while advanced stage treatments prioritize palliative integration, respiratory support coordination, and caregiver enablement.

Based on route of administration, intrathecal, intravenous, and oral delivery options shape clinical workflow, monitoring requirements, and adherence considerations. Intrathecal and intravenous routes often require hospital-based administration and specialized training, whereas oral therapies facilitate decentralized care but may encounter challenges with pharmacokinetics and central nervous system penetration. Based on distribution channel, hospital pharmacies and retail pharmacies play complementary roles where hospital pharmacies are central to specialty infusion and intrathecal administration while retail pharmacies support outpatient medication continuity and symptomatic management. Synthesizing these segmentation lenses enables stakeholders to map therapeutic attributes to operational capabilities, payer expectations, and patient access pathways.

Comparative regional dynamics outlining how regulatory, clinical research, and access frameworks across major geographies influence ALS development and commercialization

Regional dynamics materially shape regulatory pathways, clinical trial feasibility, and access frameworks for ALS treatments. In the Americas, regulatory authorities and payer systems exert strong influence on dossier design and reimbursement negotiations, while well-established research networks support rapid patient recruitment for trials that test novel mechanisms. The Americas also host concentrated centers of excellence that enable delivery of specialized intrathecal and intravenous therapies, and integrated health systems play a pivotal role in coordinating multidisciplinary care.

In Europe, Middle East & Africa, stakeholders navigate a mosaic of regulatory frameworks and payer models that require tailored evidence strategies and localized market access planning. Centralized regulatory procedures in some jurisdictions can expedite approvals for certain therapeutics, whereas heterogeneous reimbursement pathways across countries demand flexible pricing and risk-sharing models. Additionally, regional clinical networks and academic consortia are increasingly collaborating on multi-country trials that leverage shared natural history datasets and harmonized endpoints.

Asia-Pacific presents diverse development opportunities and operational considerations; several countries are investing in biotech infrastructure and clinical capacity, which opens pathways for local manufacturing partnerships and regional clinical studies. However, differences in diagnostic practices, genetic epidemiology, and healthcare financing require sponsors to adapt trial protocols and value communication strategies. Across all regions, cross-border collaboration, data sharing, and alignment on real-world evidence standards are becoming essential to support global development programs and ensure equitable patient access to emerging therapeutics.

Competitive and collaborative dynamics that reveal how portfolio strategies, manufacturing partnerships, and patient engagement investments shape ALS therapeutic success

The competitive environment in ALS therapeutics is characterized by a mix of established neurological portfolios, specialist biotech innovators, and contract organizations enabling advanced modality development. Leading pharmaceutical and biotech entities are advancing platform approaches that target molecular drivers of disease, while smaller specialists focus on niche indications, biomarker-driven cohorts, or novel delivery solutions. This diversity generates opportunities for strategic alliances, licensing arrangements, and joint development agreements that align scientific expertise with commercial scale.

Partnerships between developers and specialized contract manufacturers or service providers are increasingly central to managing the complexity of biologic and cellular product manufacturing. These collaborations help translate early-stage proof-of-concept into scalable clinical production while addressing regulatory expectations for quality and traceability. Additionally, payer-facing capabilities and global market access expertise are differentiators for companies seeking broad adoption, prompting acquisitions and collaborations that integrate clinical development with health economics and outcomes research capabilities.

Competition also extends to patient engagement and diagnostic ecosystems; organizations investing in patient registries, remote monitoring platforms, and early diagnostic initiatives can accelerate trial enrollment and strengthen real-world evidence generation. Consequently, companies that combine robust R&D pipelines with deep commercial integration, manufacturing resilience, and patient-centric evidence strategies are best positioned to navigate the complexity of the ALS treatment landscape.

Practical, high-impact strategic measures that align development, supply chain, and access initiatives to de-risk programs and accelerate patient access

Industry leaders must align strategic investments with operational realities to capture therapeutic and commercial opportunities while managing risk. First, prioritize integration between clinical development and payer evidence teams so that trial endpoints, natural history comparators, and health economic models converge early in program design. This alignment reduces downstream access friction and supports robust value communication at launch.

Second, diversify sourcing and manufacturing arrangements to enhance supply chain resilience in the face of trade policy shifts and input scarcity. Near-term tactics include multi-sourcing key intermediates, securing capacity in geographically distributed facilities, and investing in flexible fill-finish capabilities that accommodate modality-specific requirements. Third, invest in partnerships that expand diagnostic reach and patient registry participation to shorten enrollment timelines and improve the representativeness of trial populations, particularly for familial and genetically defined cohorts.

Fourth, design commercialization plans that reflect route-of-administration realities by ensuring hospital systems and specialty pharmacies are engaged early to build treatment pathways and center-of-excellence networks. Fifth, adopt adaptive evidence-generation strategies that combine randomized data with well-structured real-world evidence and digital biomarker endpoints, enabling iterative payer dialogue and post-approval data commitments. Collectively, these actions create a resilient playbook for translating scientific breakthroughs into accessible treatments while managing regulatory, operational, and commercial risk.

A mixed-methods research framework combining primary expert engagement and secondary evidence synthesis with rigorous triangulation to validate therapeutic and operational insights

The research approach underpinning this analysis combined a structured review of peer-reviewed literature, regulatory guidance, and public clinical trial registries with targeted expert interviews across clinical, regulatory, supply chain, and commercial domains. Primary engagement with neurologists, clinical trial investigators, health economists, and supply chain executives provided qualitative validation of emerging modality trends, administration challenges, and payer expectations. Secondary research synthesized scientific publications, regulatory briefing documents, and published treatment guidelines to contextualize therapeutic mechanisms and clinical endpoints.

Data triangulation was used to reconcile differing perspectives and to identify consistent themes regarding evidence needs, delivery constraints, and regional differences. Where possible, methodological rigor was preserved by cross-checking interview insights against documented clinical trial designs and public regulatory decisions. The analysis intentionally emphasized mechanistic and operational factors over proprietary market estimates to ensure the findings remain broadly applicable and decision-focused.

Limitations of the methodology include variability in public disclosure across early-stage programs, heterogeneity in regional regulatory processes, and evolving trade policy contexts that may change after the analysis cut-off. To mitigate these limitations, the study prioritized themes supported by multiple independent sources and sought corroboration from clinical and commercial experts with direct ALS experience.

Summative perspective on the intersecting scientific, operational, and payer considerations that will determine near-term translation of ALS treatment advances into patient access

The ALS therapeutic landscape is at an inflection point where molecular precision, novel delivery modalities, and evolving evidence expectations converge to reshape development and access strategies. Advances in gene-targeted and cellular approaches offer real potential for altering disease trajectory for selected patient cohorts, while improvements in symptomatic agents and monitoring technologies enhance quality-of-life management across disease stages. However, realizing these opportunities requires disciplined alignment of clinical evidence, manufacturing capacity, and payer-focused value demonstration.

Operational risks such as supply chain fragility, tariff-driven cost pressures, and the logistical demands of intrathecal and intravenous administration necessitate proactive mitigation and strategic investment. In parallel, segmentation-aware development that differentiates between familial and sporadic forms, maps stage-specific therapeutic objectives, and matches routes of administration to distribution capabilities will be critical to optimizing trial design and commercial rollout. Ultimately, organizations that couple scientific innovation with purposeful engagement across clinical networks, payers, and delivery partners will be best positioned to translate therapeutic advances into sustainable patient access and long-term impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 8.1. Medication
    • 8.1.1. Dextromethorphan/Quinidine
    • 8.1.2. Edaravone
    • 8.1.3. Riluzole
    • 8.1.4. Tofersen
  • 8.2. Therapies
    • 8.2.1. Gene Therapy
    • 8.2.2. Stem Cell Therapy

9. Amyotrophic Lateral Sclerosis Treatment Market, by Type

  • 9.1. Familial ALS
  • 9.2. Sporadic ALS

10. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage

  • 10.1. Advanced Stage Treatment
  • 10.2. Early Stage Treatment
  • 10.3. Mid Stage Treatment

11. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration

  • 11.1. Intrathecal
  • 11.2. Intravenous
  • 11.3. Oral

12. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Amyotrophic Lateral Sclerosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyotrophic Lateral Sclerosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyotrophic Lateral Sclerosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Amyotrophic Lateral Sclerosis Treatment Market

17. China Amyotrophic Lateral Sclerosis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AB Science SA
  • 18.6. Alector, Inc.
  • 18.7. Amylyx Pharmaceuticals, Inc.
  • 18.8. Apotex Inc.
  • 18.9. Aquestive Therapeutics, Inc.
  • 18.10. Ascend Pharmaceuticals LLC
  • 18.11. AstraEureka Pharmaceuticals
  • 18.12. Biogen Inc.
  • 18.13. BrainStorm Cell Limited
  • 18.14. Cipla Limited
  • 18.15. CorestemChemon Inc.
  • 18.16. Coya Therapeutics, Inc.
  • 18.17. Cytokinetics, Incorporated
  • 18.18. Dewpoint Therapeutics, Inc.
  • 18.19. DR. REDDY'S LABORATORIES LIMITED
  • 18.20. F. Hoffmann-La Roche Ltd
  • 18.21. Genervon Biopharmaceuticals, LLC
  • 18.22. GlaxoSmithKline PLC
  • 18.23. Implicit Bioscience Ltd.
  • 18.24. Ionis Pharmaceuticals, Inc.
  • 18.25. ITF Pharma, Inc.
  • 18.26. Kringle Pharma, Inc.
  • 18.27. Mitsubishi Tanabe Pharma Corporation
  • 18.28. Neurimmune AG
  • 18.29. Novartis AG
  • 18.30. ONO PHARMACEUTICAL CO., LTD.
  • 18.31. Orion Corporation
  • 18.32. Orphazyme A/S
  • 18.33. Otsuka Pharmaceutical Co., Ltd.
  • 18.34. Pfizer, Inc.
  • 18.35. Sanofi SA
  • 18.36. Sun Pharmaceutical Industries Ltd
  • 18.37. Teva Pharmaceutical Industries Ltd.
  • 18.38. Treeway B.V.
  • 18.39. Viatris Inc.
  • 18.40. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 139. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 141. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 163. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 171. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 173. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)